Last reviewed · How we verify
NCT06804395
CanScan; Community-based Registry to Assess, Address and advaNce SCreening for cANcer Prevention and Management
trial in Cancer Risk in 10,000 participants. Currently enrolling.
1 October 2034
Quick facts
| Lead sponsor | Hackensack Meridian Health |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 10,000 |
| Start date | 1 October 2024 |
| Primary completion | 1 October 2034 |
| Estimated completion | 1 October 2034 |
| Sites | 1 location across United States |
Conditions studied
- Cancer Risk — all drugs for Cancer Risk →
Sponsor
Hackensack Meridian Health — full company profile →
Who can join
18 and older, any sex, with Cancer Risk. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Early diagnosis of cancer allows for better treatment outcomes, higher survival rates, and lower costs of care. It is shown that cancer monitoring for cancer in at-risk populations is a key component in early diagnosis. The HMH Hennessey Institute for Cancer prevention and Applied Molecular Science (HICAP) is a newly founded institute, providing clinical services for cancer screening and risk assessment to the community, as well as research in cancer risk and prevention. The CanScan registry will prospectively collect data from participants in the form of questionnaires. The registry will also capture data that is collected as per non-research assessments, for participants who consent to participate. The registry will facilitate better understanding of cancer risk, screening, and diagnostics.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06804395
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cancer Risk
Currently open trials in the same condition.
- NCT07121972 — Mirai-MRI: Validation of AI Models for Breast Cancer Risk · NA · recruiting
- NCT06864260 — Cancer PRevention Through Enhanced EnvironMenT · NA · active not recruiting
- NCT05463796 — InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer · recruiting
- NCT06653478 — Development and Demonstration of Intelligent Assessment Based on Multi-modal Information Fusion for Tumor Risk and Diagn · recruiting
- NCT06939049 — Development of New Methodologies and Innovative Tools for the diagnoSi and Therapeutic Treatment of uMAni Epithelial Tum · recruiting
Other Hackensack Meridian Health trials
Trials by the same sponsor.
- NCT06785402 — Ceftriaxone for Post-Treatment Lyme Disease · Phase 1, PHASE2 · recruiting
- NCT06987708 — Evaluating the Impact of a 12-month Multi-Modal Lifestyle Management Intervention on Disease Relevant Biomarkers · NA · not yet recruiting
- NCT06575894 — Implementing Mental Health Programs Across Communities in Iowa & Indiana for Transformation · NA · not yet recruiting
- NCT07442669 — Utilization of Lung Ultrasound Score in Decision for Minimally Invasive Surfactant Administration · NA · not yet recruiting
- NCT06991166 — OBWELL: Innovative Psychotherapeutic Intervention to Treat Postpartum Depression · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06804395 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hackensack Meridian Health
- Last refreshed: 19 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06804395.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing